(Q50587563)

16 March 2018

title

Enhancing the response to interferon-alpha. (English)

1 reference

16 March 2018

author name string

F Begemann

series ordinal

1

1 reference

16 March 2018

H Jablonowski

series ordinal

2

1 reference

16 March 2018

publication date

1 June 1999

1 reference

16 March 2018

Journal of Clinical Virology

published in

1 reference

16 March 2018

volume

13

1 reference

16 March 2018

issue

1-2

1 reference

16 March 2018

page(s)

1-7

1 reference

16 March 2018

Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Tumor necrosis factor and interferon as prognostic markers in human immunodeficiency virus (HIV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Mechanisms of action of interferons

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Interferons in the pathogenesis and treatment of human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

The progression of HCV-associated liver disease in a cohort of haemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Dynamics of hepatitis C viremia following interferon-alpha administration

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900009-8

7 January 2021

10.1016/S1386-6532(99)00009-8

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018